HOXB9 and ovarian cancer: Similar to ovarian cancer, miR-192 treatment mediated a robust downregulation of EGR1 and HOXB9 levels (Fig. 5b) and significant decreases in several angiogenic factors including IL6, IL8 and EFNA1 (Fig. 5c); consistent with the pattern observed after siEGR1/siHOXB9 treatment (Supplementary Fig. 6b,c).